此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission (ADMIRE)

2013年11月21日 更新者:AbbVie (prior sponsor, Abbott)

A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission (ADMIRE)

The purpose of this pilot study is to investigate the possibility of discontinuing adalimumab therapy in patients with rheumatoid arthritis who are in stable remission after treatment with adalimumab in combination with methotrexate.

研究概览

详细说明

Treatments with adalimumab and other tumor necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), are usually continued indefinitely. Information concerning the possibility of discontinuing anti-TNF therapy in RA patients who are in remission is limited. This is a pilot study in one country to study the effect of adalimumab discontinuation. The objective is to assess the proportion of patients with established RA in stable remission (Disease Activity Score [DAS]28 <2.6) after treatment with adalimumab in combination with methotrexate, in whom it is possible to discontinue adalimumab and to compare the remission rates among patients on sustained therapy with adalimumab + methotrexate with remission rates among patients who discontinued adalimumab.

Rheumatoid arthritis patients in stable remission (DAS28 < 2.6) treated with adalimumab + methotrexate were randomized in a 1:1 ratio to continue with adalimumab treatment or discontinue adalimumab treatment for the following 52 weeks. Subsequently an observational extension was conducted to observe patients treated at the discretion of the investigator. The observational extension period lasted until Weeks 105 - 156 (average Week 125) and consisted of one follow-up visit. Participants randomized to discontinue adalimumab therapy will be reinstituted to adalimumab if DAS28-score increases by >1.2 units from baseline and/or is scored ≥2.6 at any visit during the study and will be followed for an additional 12 weeks.

研究类型

介入性

注册 (实际的)

33

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Linkoping、瑞典、581 85
        • Site Reference ID/Investigator# 22062
      • Lund、瑞典、22185
        • Site Reference ID/Investigator# 14022
      • Malmo、瑞典、20502
        • Site Reference ID/Investigator# 14023
      • Oskarstroem、瑞典、31392
        • Site Reference ID/Investigator# 14301
      • Skoevde、瑞典、54185
        • Site Reference ID/Investigator# 20241
      • Stockholm、瑞典、171 76
        • Site Reference ID/Investigator# 4918
      • Stockholm、瑞典、SE-141 86
        • Site Reference ID/Investigator# 14021
      • Uppsala、瑞典、75185
        • Site Reference ID/Investigator# 14302

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age ≥18 years.
  • Diagnosis of RA as defined by the 1987-revised American College of Rheumatology (ACR)-classification and has positive rheumatoid factor (RF) test or erosion on X-ray of hands or feet.
  • Currently treated with adalimumab and MTX (at least 10 mg/week; orally or subcutaneously).
  • In remission as defined by disease activity score (DAS)28 <2.6 for at least the past 3 months.
  • Concomitant disease-modifying anti-rheumatic drug (DMARD) or oral corticosteroid therapy has been stable for at least 3 months at study entry.
  • Female subject is either not of childbearing potential or is practicing a relevant method of birth control.
  • Subject is judged to be in good general health.
  • Subjects must be able and willing to provide written informed consent.
  • Subjects must be able and willing to self-administer subcutaneous (SC) injections or have a qualified person available to administer SC injections.

Exclusion Criteria:

  • Treatment with intra-articular or parenteral administration of corticosteroids in the preceding 4 weeks.
  • Oral prednisone or prednisone equivalent > 10 mg/day at baseline.
  • Joint surgery within the preceding two months.
  • History of acute inflammatory joint disease other than RA.
  • Treatment with any investigational drug within 30 days or 5 half lives, whichever is longer prior to study entry.
  • Poorly controlled medical condition, which would put the subject at risk by participation in the study.
  • History of clinically significant hematologic, renal or liver disease.
  • Diagnosis of, or history suggestive of, central nervous system (CNS) demyelinating disease.
  • History of cancer or lymphoproliferative disease other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma of the cervix.
  • History of listeriosis, histoplasmosis, untreated tuberculosis (TB), persistent chronic infections, or recent active infections.
  • Known immune deficiency or human immunodeficiency virus (HIV).
  • Female who is pregnant or breast-feeding or considering becoming pregnant or breast feeding during the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Adalimumab + MTX
Participants continued treatment with adalimumab 40 mg subcutaneously every other week plus methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
40 mg every other week via subcutaneous injection
其他名称:
  • ABT-D2E7
  • 修美乐
At least 10 mg/week administered orally or subcutaneously
实验性的:Methotrexate
Participants discontinued adalimumab and continued to receive methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. Participants with a significant increase in RA disease activity were re-instituted to adalimumab 40 mg every other week (rescue arm). After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
At least 10 mg/week administered orally or subcutaneously

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants in Remission at Week 28
大体时间:Week 28

Remission is defined as a Disease Activity Score (DAS)28 of less than 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.

In this analysis participants in the methotrexate treatment group with a DAS28 score ≥ 2.6 (and thus allocated to rescue therapy with adalimumab) prior to Week 28 were considered not to be in remission at Week 28. Also, participants who did not complete 28 weeks were considered not in remission.

Week 28
Percentage of Participants in Remission at Week 28 in the Full Analysis Set 2 (FAS2)
大体时间:Week 28

Remission is defined as a Disease Activity Score (DAS)28 of less than 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.

In this analysis participants in the methotrexate treatment group with a DAS28 score ≥ 2.6 (and thus allocated to rescue therapy with adalimumab) prior to Week 28 were considered not to be in remission at Week 28. Also, participants who did not complete 28 weeks were considered not in remission.

Week 28

次要结果测量

结果测量
措施说明
大体时间
Percentage of Participants in Remission at Week 52
大体时间:Week 52

Remission is defined as a Disease Activity Score (DAS)28 of less than 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.

In this analysis participants in the methotrexate treatment group with a DAS28 score ≥ 2.6 (and thus allocated to rescue therapy with adalimumab) prior to Week 52 were considered not to be in remission at Week 52. Also, participants who did not complete 52 weeks were considered not in remission.

Week 52
Percentage of Participants in Remission at Week 52 (FAS2)
大体时间:Week 52

Remission is defined as a Disease Activity Score (DAS)28 of less than 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity. Also, participants who did not complete 52 weeks were considered not in remission.

In this analysis participants in the methotrexate treatment group with a DAS28 score ≥ 2.6 (and thus allocated to rescue therapy with adalimumab) prior to Week 52 were considered not to be in remission at Week 52.

Week 52
Number of Participants With a Flare
大体时间:Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, and 52
Flare is defined as DAS28 ≥2.6 or an increase from Baseline in the DAS28 of greater than 1.2 units. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.
Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, and 52
Percentage of Participants With Response to Adalimumab Treatment (Return to Baseline DAS28 + ≤ 10%) After a Flare
大体时间:1 to 4 weeks, 5 to 8 weeks, 9 to 12 weeks, and 13 to 16 weeks after reinstitution of adalimumab rescue therapy

For participants with a flare and treated with adalimumab rescue therapy, response was defined as return to Baseline DAS28 + ≤ 10% after reinstitution of adalimumab (rescue therapy).

The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.

1 to 4 weeks, 5 to 8 weeks, 9 to 12 weeks, and 13 to 16 weeks after reinstitution of adalimumab rescue therapy
Percentage of Participants With Response to Adalimumab Treatment (DAS28 <2.6 or DAS28 Decrease >1.2 Units) After a Flare
大体时间:1 to 4 weeks, 5 to 8 weeks, 9 to 12 weeks, and 13 to 16 weeks after reinstitution of adalimumab rescue therapy
For participants with a flare and treated with adalimumab rescue therapy, response was defined as DAS28 less than 2.6 or DAS28 decrease of greater than 1.2 units after reinstitution of adalimumab (rescue therapy). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein (CRP), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.
1 to 4 weeks, 5 to 8 weeks, 9 to 12 weeks, and 13 to 16 weeks after reinstitution of adalimumab rescue therapy
Health Assessment Questionnaire (HAQ) Total Score by Visit
大体时间:Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)
Physical function was evaluated using the Health Assessment Questionnaire - Disability Index (HAQ-DI), a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI < 0.5.
Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)
European Quality of Life-5 Dimensions (EQ-5D) Mobility Score by Visit
大体时间:Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)

The EQ-5D is an international, standardized, generic instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their mobility health state:

Level 1: I have no problems in walking about;

Level 2: I have some problems in walking about;

Level 3: I am confined to bed.

Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)
European Quality of Life-5 Dimensions (EQ-5D) Self-care Score by Visit
大体时间:Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)

The EQ-5D is an international, standardized, generic instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their self-care health state:

Level 1: I have no problems with self-care;

Level 2: I have some problems washing or dressing myself;

Level 3: I am unable to wash or dress myself.

Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)
European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score by Visit
大体时间:Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)

The EQ-5D is an international, standardized, generic instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their health state with regard to usual activities (work, study, housework, family, or leisure activities):

Level 1: I have no problems performing my usual activities;

Level 2: I have some problems performing my usual activities;

Level 3: I am unable to perform my usual activities.

Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)
European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score by Visit
大体时间:Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)

The EQ-5D is an international, standardized, generic instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their pain/discomfort health state:

Level 1: I have no pain or discomfort;

Level 2: I have moderate pain or discomfort;

Level 3: I have extreme pain or discomfort.

Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)
European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score by Visit
大体时间:Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)

The EQ-5D is an international, standardized, generic instrument for describing and valuing health status. Participants were asked to indicate which of the following statements best describes their anxiety/depression health state:

Level 1: I am not anxious or depressed;

Level 2: I am moderately anxious or depressed;

Level 3: I am extremely anxious or depressed.

Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)
European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) by Visit
大体时间:Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)
The EQ-5D is an international, standardized, generic instrument for describing and evaluating health status. Health status is assessed by patients evaluating their health on a vertical, visual analog scale from 0 to 100 where the endpoints are labeled 'Worst imaginable health state' (0) and 'Best imaginable health state' (100).
Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)
Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale by Visit
大体时间:Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)
The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions on a scale from 'not at all' (0) to 'very much' (4). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue.
Baseline and Weeks 4, 8, 12, 20, 28, 36, 44, 52, and 104-156 (extension period visit)
Work Instability Score (WIS) for RA: I'm Getting up Earlier Because of Arthritis
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 1, participants selected either Yes or No if the following statement currently applied to them or not: I'm getting up earlier because of the arthritis.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I Get Very Stiff at Work
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 2, participants selected either Yes or No if the following statement currently applied to them or not: I get very stiff at work.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I'm Finding my Job is About All I Can Manage
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 3, participants selected either Yes or No if the following statement currently applied to them or not: I'm finding my job is about all I can manage.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: The Stress of my Job Makes my Arthritis Flare
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 4, participants selected either Yes or No if the following statement currently applied to them or not: The stress of my job makes my arthritis flare.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I'm Finding Any Pressure on my Hands is a Problem
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 5, participants selected either Yes or No if the following statement currently applied to them or not: I'm finding any pressure on my hands is a problem.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I Get Good Days and Bad Days at Work
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 6, participants selected either Yes or No if the following statement currently applied to them or not: I get good days and bad days at work.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I Can Get my Job Done, I'm Just a Lot Slower
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 7, participants selected either Yes or No if the following statement currently applied to them or not: I can get my job done, I'm just a lot slower.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: If I Don't Reduce my Hours I May Have to Give up Work
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 8, participants selected either Yes or No if the following statement currently applied to them or not: If I don't reduce my hours I may have to give up work.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I am Very Worried About my Ability to Keep Working
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 9, participants selected either Yes or No if the following statement currently applies to them or not: I am very worried about my ability to keep working.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I Have Pain or Stiffness All the Time at Work
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 10, participants selected either Yes or No if the following statement currently applies to them or not: I have pain or stiffness all the time at work.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I Don't Have the Stamina to Work Like I Used to
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 11, participants selected either Yes or No if the following statement currently applies to them or not: I don't have the stamina to work like I used to.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I Have Used my Vacation so That I Don't Have to Take Sick Leave
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 12, participants selected either Yes or No if the following statement currently applies to them or not: I have used my vacation so that I don't have to take sick leave.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I Push Myself to go to Work Because I Don't Want to Give in to the Arthritis
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 13, participants selected either Yes or No if the following statement currently applies to them or not: I push myself to go to work because I don't want to give in to the arthritis.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: Sometimes I Can't Face Being at Work All Day
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 14, participants selected either Yes or No if the following statement currently applies to them or not: Sometimes I can't face being at work all day.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I Have to Say No to Certain Things at Work
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 15, participants selected either Yes or No if the following statement currently applies to them or not: I have to say no to certain things at work.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I've Got to Watch How Much I do Certain Things at Work
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 16, participants selected either Yes or No if the following statement currently applies to them or not: I've got to watch how much I do certain things at work.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I Have Great Difficulty Opening Some of the Doors at Work
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 17, participants selected either Yes or No if the following statement currently applies to them or not: I have great difficulty opening some of the doors at work.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I Have to Allow Myself Extra Time to do Some Jobs
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 18, participants selected either Yes or No if the following statement currently applies to them or not: I have to allow myself extra time to do some jobs.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: It's Very Frustrating Because I Can't Always do Things at Work
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 19, participants selected either Yes or No if the following statement currently applies to them or not: It's very frustrating because I can't always do things at work.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I Feel I May Have to Give up Work
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 20, participants selected either Yes or No if the following statement currently applies to them or not: I feel I may have to give up work.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I Get on With the Work But Afterwards I Have a Lot of Pain
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 21, participants selected either Yes or No if the following statement currently applies to them or not: I get on with the work but afterwards I have a lot of pain.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: When I'm Feeling Tired All the Time Work is a Grind
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 22, participants selected either Yes or No if the following statement currently applies to them or not: When I'm feeling tired all the time work is a grind.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability Score (WIS) for RA: I'd Like Another Job But I am Restricted to What I Can do
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
Work Instability (defined as the mismatch between the person's abilities and the demands of work) Score is a 23-item questionnaire designed to indicate the participant's level of risk for work disability. In question 23, participants selected either Yes or No if the following statement currently applied to them or not: I'd like another job but I am restricted to what I can do.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Productivity and Activity Impairment (WPAI): Currently Employed
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
The Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire was used to assess work and activity impairment due to symptoms of rheumatoid arthritis in the last 7 days. The self-administered questionnaire consists of 6 questions. Question 1 asks participants to indicate if they are currently employed or working for pay (Yes or No).
Baseline and at Weeks 12, 28, 52, and 104-156
Work Productivity and Activity Impairment (WPAI): Hours Missed From Work
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
The Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire was used to assess work and activity impairment due to symptoms of rheumatoid arthritis in the last 7 days. The self-administered questionnaire consists of 6 questions. Question 2 asks participants who are employed or working for pay to indicate the number of hours missed from work due to problems associated with their rheumatoid arthritis.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Productivity and Activity Impairment (WPAI): Hours Missed From Work for Other Reasons
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
The Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire was used to assess work and activity impairment due to symptoms of rheumatoid arthritis in the last 7 days. The self-administered questionnaire consists of 6 questions. Question 3 asks participants who are employed or working for pay to indicate the number of hours missed from work due to reasons other than rheumatoid arthritis.
Baseline and at Weeks 12, 28, 52, and 104-156
Work Productivity and Activity Impairment (WPAI): Hours Worked
大体时间:Baseline and at Weeks 12, 28, 52 and 104-156
The Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire was used to assess work and activity impairment due to symptoms of rheumatoid arthritis in the last 7 days. The self-administered questionnaire consists of 6 questions. Question 4 asks participants who are employed or working for pay to indicate the number of hours actually worked during the past 7 days.
Baseline and at Weeks 12, 28, 52 and 104-156
Work Productivity and Activity Impairment (WPAI): Work Productivity
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
The Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire was used to assess work and activity impairment due to symptoms of rheumatoid arthritis in the last 7 days. The self-administered questionnaire consists of 6 questions. Question 5 asks participants who are employed or working for pay to indicate how much their rheumatoid arthritis impaired their productivity while working in the past 7 days on a scale from 0 (no effect) to 10 (completely prevented from working).
Baseline and at Weeks 12, 28, 52, and 104-156
Work Productivity and Activity Impairment (WPAI): Daily Activities
大体时间:Baseline and at Weeks 12, 28, 52, and 104-156
The Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire was used to assess work and activity impairment due to symptoms of rheumatoid arthritis in the last 7 days. The self-administered questionnaire consists of 6 questions. Question 6 asks participants to indicate how much their rheumatoid arthritis affected their ability to do their regular daily activities such as housework, childcare, exercising, shopping, studying, etc, in the past 7 days on a scale from 0 (no effect) to 10 (completely prevented from doing daily activities).
Baseline and at Weeks 12, 28, 52, and 104-156
Change From Baseline in Radiological Modified Total Sharp Score
大体时间:Baseline, Week 52, and Weeks 104-156
The van der Heijde modified Total Sharp Score (mTSS) is a measure of the level of joint damage. X-rays of hands and feet were taken at Baseline, Week 52 and the Week 104-156 visit. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
Baseline, Week 52, and Weeks 104-156

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Mikael Heimburger, MD、AbbVie AB

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2009年1月1日

初级完成 (实际的)

2012年9月1日

研究完成 (实际的)

2012年9月1日

研究注册日期

首次提交

2008年12月12日

首先提交符合 QC 标准的

2008年12月12日

首次发布 (估计)

2008年12月16日

研究记录更新

最后更新发布 (估计)

2013年12月16日

上次提交的符合 QC 标准的更新

2013年11月21日

最后验证

2013年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅